ストックスクリーナーアプリを入手
2.93
3.93%
-0.12
アフターアワーズ：
3.00
0.07
+2.39%
前日終値:
$3.05
開ける：
$3.08
24時間の取引高:
248.62K
Relative Volume:
1.24
時価総額：
$165.61M
収益：
$26.03M
当期純損益:
$-17.12M
株価収益率:
-2.9412
EPS:
-0.9962
ネットキャッシュフロー:
$-24.53M
1週間 パフォーマンス:
+11.41%
1か月 パフォーマンス:
+8.92%
6か月 パフォーマンス:
+56.68%
1年 パフォーマンス:
+253.06%
1日の値動き範囲:
$2.85
$3.1391
1週間の範囲:
$2.58
$3.1494
52週間の値動き範囲:
$0.65
$3.82
Connect Biopharma Holdings Ltd Stock (CNTB) Company Profile
名前
Connect Biopharma Holdings Ltd
セクター
電話
858-727-1040
住所
3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO
Compare CNTB vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CNTB
Connect Biopharma Holdings Ltd
|
2.93 | 172.39M | 26.03M | -17.12M | -24.53M | -0.9962 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Connect Biopharma Holdings Ltd Stock (CNTB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-01 | 開始されました | Lake Street | Buy |
| 2025-10-31 | 開始されました | BTIG Research | Buy |
| 2025-06-12 | 開始されました | H.C. Wainwright | Buy |
| 2024-03-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-13 | 開始されました | Jefferies | Buy |
| 2021-04-13 | 開始されました | Piper Sandler | Overweight |
| 2021-04-13 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Connect Biopharma Holdings Ltd (CNTB) 最新ニュース
Connect Biopharma Holdings (CNTB) insider-linked stake of 9.6% disclosed - Stock Titan
Q1 Earnings Estimate for CNTB Issued By HC Wainwright - MarketBeat
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Director at Connect Biopharma (CNTB) takes shares instead of cash pay - Stock Titan
[Form 4] Connect Biopharma Holdings Ltd Insider Trading Activity - Stock Titan
Connect Biopharma (NASDAQ:CNTB) Director James Huang Acquires 1,160,000 Shares - MarketBeat
Entity tied to CNTB director James Huang buys 1.16M shares in open market - Stock Titan
Connect Biopharma (NASDAQ: CNTB) holder Panacea adds 1.16M shares - Stock Titan
Connect Biopharma (NASDAQ:CNTB) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
ETFs Investing in Connect Biopharma Holdings Ltd. Stocks - TradingView — Track All Markets
Connect Biopharma Holdings Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update - The Manila Times
Rademikibart drives Connect Biopharma (NASDAQ: CNTB) asthma and COPD strategy - Stock Titan
[8-K] Connect Biopharma Holdings Ltd Reports Material Event - Stock Titan
Connect Biopharma (NASDAQ:CNTB) Receives "Buy" Rating from BTIG Research - MarketBeat
BTIG Reiterates Buy Rating on Connect Biopharma Hldgs (CNTB) | C - gurufocus.com
BTIG reiterates Buy on Connect Biopharma stock after Phase 1 data - Investing.com Australia
BTIG reiterates Buy on Connect Biopharma stock after Phase 1 data By Investing.com - Investing.com South Africa
Connect Biopharma Announces Positive Phase 1 Results for IV Rademikibart, Showing Rapid Lung Function Improvement in Asthma and COPD Patients - Minichart
Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Green Bay Press-Gazette
Connect Biopharma touts rapid IV rademikibart FEV1 gains; Phase 3 atopic dermatitis data impresses - MarketBeat
Connect Biopharma reports positive Phase 1 data for asthma drug By Investing.com - Investing.com Australia
Connect Biopharma raises $20.2 million in private placement By Investing.com - Investing.com South Africa
Connect Biopharma stock jumps on positive drug trial results By Investing.com - Investing.com India
Connect Biopharma Announces $20.2 Million Private Placement Financing - Bitget
Connect Biopharma raises $20.2 million in private placement - Investing.com
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD - Bitget
Connect Biopharma Raises $20.2 Million in Private Placement of 6.13 Million Shares at $3.25 - TradingView
Connect Biopharma reports positive Phase 1 data for asthma drug - Investing.com
Connect Biopharma (NASDAQ: CNTB) nets $20.2M and reports promising rademikibart results - Stock Titan
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study - GlobeNewswire
Connect Biopharma Announces Positive Topline Data from its - GlobeNewswire
CNTB Stock Price, Quote & Chart | CONNECT BIOPHARMA HOLDINGS L (NASDAQ:CNTB) - ChartMill
Connect Biopharma (CNTB) Expected to Announce Earnings on Monday - MarketBeat
CNTB SEC FilingsConnect Biopharma Holdings Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
If You Invested $1,000 in Connect Biopharma Holdings Ltd (CNTB) - Stock Titan
CONNECT BIOPHARMA HOLDINGS L (CNTB) Earnings History & Surprises - ChartMill
Connect Biopharma (CNTB) director linked fund reports 12M-share holding - Stock Titan
Epidermolysis Bullosa Market Set for Significant Upswing During the Forecast Period (2025-2034) Amid Rising Therapeutic Advancements | DelveInsight – Company AnnouncementFT.com - Financial Times
[Form 3] Connect Biopharma Holdings Ltd Initial Statement of Beneficial Ownership - Stock Titan
Connect Biopharma (CNTB) president discloses share and option holdings - Stock Titan
Connect Biopharma (CNTB) CEO details stock option and share holdings - Stock Titan
Connect Biopharma (CNTB) SVP lists Ordinary Shares and option grants - Stock Titan
Connect Biopharma (NASDAQ: CNTB) director reports initial share and option holdings - Stock Titan
Connect Biopharma (CNTB) director lists stock option and share stakes - Stock Titan
Connect Biopharma (NASDAQ: CNTB) director reports initial stock option holdings - Stock Titan
Connect Biopharma Holdings Ltd (CNTB) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):